Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors

Cancer

Volumn 80, Issue 6, 1997, Pages 1134-1140

  Budd, G T ^a,e   Ganapathi, Ram ^a   Adelstein, David J ^a   Pelley, Robert ^a   Olencki, Thomas ^a   Petrus, John ^b   McLain, Denise ^a   Zhang, Jianliang ^c   Capizzi, Robert ^c,d   Bukowski, Ronald M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b AKRON GENERAL MEDICAL CENTER   (United States)

^c US Bioscience   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Amifostine; Carboplatin; Cytoprotection; Thrombocytopenia

Indexed keywords

AMIFOSTINE; CARBOPLATIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; AMIFOSTINE; ANTINEOPLASTIC AGENTS; BONE MARROW; CARBOPLATIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPHILS; PLATELET COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0030826795     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970915)80:6<1134::AID-CNCR17>3.0.CO;2-9     Document Type: Article

References (21)

1. Schuchter LM, Luginbuhl WE, Meropol NJ. The current status of toxicity protectants in cancer therapy. Semin Oncol 1992;19:6,742-51.
2. Millar JL, McElwain TJ, Clutterbuck RD, Wist EA. The modification of melphalan toxicity in tumor bearing mice by S-2-(3-aminopropylamino)-ethylphosporothioic acid (WR-2721). Am J Clin Oncol 1982;5:321-8.
3. Wasserman TH, Phillips TL, Ross G, Kane LJ. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFU's by WR-2721. Cancer Clin Trials 1981;4:3-6.
4. Yuhas JM. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine. Cancer Treat Rep 1979;63:971-6.
5. Yuhas JM, Culo F. Selective inhibition of the nephrotoxicity of cis-Dichlorodiammineplatinum (II) by WR-2721 without altering its antitumor properties. Cancer Treat Rep 1980;64:57-64.
6. Yuhas JM, Spellman JM, Jordan SW, Pardini MC, Afzal SM, Culo F. Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer 1980;42:574-85.
7. Calabro-Jones PM, Aguilera JA, Ward JF, Smoluk GD, Fahey RC. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 1988;48:3634-40.
8. Calabro-Jones P, Fahey RC, Smoluk GD, Ward JF. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol 1985;47:23-7.
9. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosporothioic acid. Cancer Res 1980;40:1519-24.
10. Turrisi AT, Glover DJ, Hurwitz S, Click S, Norfleet AL, Weiler C, et al. Final report of the Phase I trial of single-dose WR-2721. Cancer Treat Rep 1986;70:1389-93.
11. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J. Clin Oncol 1996;14:2101-12.
12. Glover D, Click JH, Weiler C, Hurowitz S, Kligerman MM. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled Phase II trial. J Clin Oncol 1986;4:584-8.
13. Glover D, Click J, Weiler C, Fox K, Turrisi A, Kligerman MM. Phase I/II trials of WR-2721 and cisplatin. Int J Radiat Oncol Biol Phys 1986;12:1509-12.
14. Lyss AP. Enzymes and random synthetics. In: Perry MC, editor. The chemotherapy sourcebook. Baltimore: Williams & Wilkins, 1992:398-412.
15. Canetta R, Franks C, Smaldone L, Bragman K, Rozencweig M. Clinical status of carboplatin. Oncology 1987;1:61-9.
16. Treskes M, Boven E, van de Loosdrecht AA, Wijffels JF, Cloos J, Peters GJ, et al. Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer 1994;30A(2):183-7.
17. Budd GT, Ganapathi R, Bauer L, Murthy S, Adelstein D, Weick J, et al. Phase I study of WR-2721 and carboplatin. Eur J Cancer 1993;29A:1122-6.
18. Egorin MJ, Van Echo DA, Olman EA, Whitacre WY, Forrest A, Aisner J. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylaplatinum. Cancer Res 1985;45:6502-6.
19. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
20. Betticher DC, Anderson H, Ranson M, Meely K, Oster W, Thatcher N. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small cell lung cancer, a randomized Phase II study. Br J Cancer 1995;72:1551-5.
21. Korst AEC, Gall HE, Vermorken JB, Fichtinger-Schepman AMI, van dr Vijgh WIF. Influence of amifostine on the pharmacokinetics of caroplatin in patients with solid tumors [abstract 374]. Proc Am Soc Clin Oncol 1995;14:172.